RC2NB Pioneers MS Research and Personalized Care in Clinnova Initiative
The Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB) is an internationally known institution providing an end-to-end approach; advancing research, clinical care, and innovation to transform the lives of patients with Multiple Sclerosis and other neuroimmunological diseases. As a core partner in the Clinnova project, RC2NB plays a leading role in Switzerland, developing cutting-edge tools that facilitate a deeper understanding of neuroimmunological diseases. By focusing on personalized disease management and novel diagnostic approaches, we are advancing both the science and treatment of MS.
In collaboration with the University of Basel, University Hospital Basel, and Indivi, RC2NB integrates interdisciplinary expertise to enhance patient outcomes. Our research spans a broad spectrum, from early diagnosis to the management of progressive MS. As part of Clinnova-MS, RC2NB is enrolling patients at various stages of the disease, including those transitioning to progressive MS. Data from these patients, including biological samples, imaging, and cognitive assessments, are collected and analyzed to better understand disease progression. Furthermore, patient-reported outcomes and mobility data are continuously monitored using the dreaMS app (Indivi), which incorporates user-specific, dynamically adaptive assessments of cognition to enhance the detection of early impairment and decline.
RC2NB’s participation in the federated learning Clinnova network ensures that data privacy remains a top priority. Each center, including ours, maintains control of local patient data while contributing to collective learning through federated models. Supported by CHF 4 million in funding from the Canton of Basel-Stadt, this ambitious initiative underscores our commitment to shaping the future of MS care through scientific innovation and collaboration.
By combining state-of-the-art research with clinical expertise, RC2NB is uniquely positioned to lead the development of new therapies, offering patients access to the latest advancements in neuroimmunology and personalized medicine.
